

FILE 'HOME' ENTERED AT 11:17:57 ON 30 MAR 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:18:10 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10607175_NEW.str



chain nodes :

8 9 10 15 16 17 18 19

ring nodes :

1 2 3 4 5 6

chain bonds :

2-15 5-8 8-9 9-10 15-16 15-19 16-17 16-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

5-8 8-9 9-10 15-16 15-19 16-17 16-18
 exact bonds :
 2-15
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:CH2,NH,O,S

G2:OH,SH,COOH,NH2,Cl,Br,I

G3:H,Cy,Hy,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:CLASS
 15:CLASS
 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:18:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 169763 TO ITERATE

1.2% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**

L2 1 SEA SSS SAM L1

FULL SEARCH INITIATED 11:18:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3378929 TO ITERATE

1071 ANSWERS


1125 ANSWERS

L3 1125 SEA SSS FUL L1


```
L3      1125 ANSWERS      REGISTRY  COPYRIGHT 2007 ACS on STN
IN      INDEX NAME NOT YET ASSIGNED
SQL     9
MF      C76 H115 N17 O22 S
```


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B









PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 1125 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
SQL 9
MF C63 H102 N14 O22 S

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file medline, caplus, wpids, uspatfull

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

173.00

173.21

FILE 'MEDLINE' ENTERED AT 11:20:14 ON 30 MAR 2007

FILE 'CAPLUS' ENTERED AT 11:20:14 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:20:14 ON 30 MAR 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 11:20:14 ON 30 MAR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12

SAMPLE SEARCH INITIATED 11:20:19 FILE 'WPIDS'

SAMPLE SCREEN SEARCH COMPLETED - 16401 TO ITERATE

6.1% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 160508 TO 167512

PROJECTED ANSWERS: 157 TO 499

=> d 14 1-4 ibib, abs, hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:308396 CAPLUS Full-text

DOCUMENT NUMBER: 140:339072

TITLE: Preparation of benzamide derivatives as LPA receptor antagonists

INVENTOR(S): Terakado, Masahiko; Nakade, Shinji; Seko, Takuya; Takaoka, Yoshikazu

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 304 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031118	A1	20040415	WO 2003-JP6680	20030528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003241836	A1	20040423	AU 2003-241836	20030528
EP 1553075	A1	20050713	EP 2003-733131	20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006148830	A1	20060706	US 2005-530249	20050404
PRIORITY APPLN. INFO.:			JP 2002-291137	A 20021003
			WO 2003-JP6680	W 20030528

OTHER SOURCE(S): MARPAT 140:339072

GI



AB The title compds. I [wherein R = (un)substituted aliphatic hydrocarbyl or cyclyl; G = a bond or a spacer; T = CH₂ or a spacer; J = N or CH; B = (un)substituted aliphatic hydrocarbyl or cyclyl; K = a bond or a spacer; Q = a bond or a spacer; ring D = (un)substituted cyclic ring; L = a bond or a spacer; ring E = (un)substituted cyclic ring; n = 0 or 1; M = a bond or a spacer; Z = a acid group] or prodrugs, or salts thereof are prepared as lysophosphatidic acids (LPA) receptor antagonists. For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activity with IC₅₀ of 0.095 μM against human EDG-2. I are useful for the treatment of urinary diseases, cancer-related diseases, proliferative diseases, inflammatory immune diseases, diseases caused by secretion failures, brain-related diseases, etc. (no data). Formulations containing I as an active ingredient were also described.


IT 679790-63-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

RN 679790-63-7 CAPLUS

CN Benzeneacetic acid, 4-[[[3-(4-chlorophenyl)propyl](3,5-dimethoxybenzoyl)amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L4 ANSWER 3 OF 4 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L4 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2006:175380 USPATFULL Full-text

TITLE: Lpa receptor antagonist

INVENTOR(S): Terakado, Masahiko, Mishima-gun, JAPAN
Nakade, Shinji, Mishima-gun, JAPAN
Seko, Takuya, Osaka-shi, JAPAN
Takaoka, Yoshikazu, Mishima-gun, JAPAN

PATENT ASSIGNEE(S): ONO Pharmaceutical Co., LTD. (non-U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2006148830 A1 20060706
 APPLICATION INFO.: US 2003-530249 A1 20030528 (10)
 WO 2003-JP6680 20030528
 20050404 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-291137	20021003
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US	
NUMBER OF CLAIMS:	78	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7160	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the general formula (I): ##STR1## (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 679790-63-7P

(drug candidate; preparation of benzamide derivs. as LPA receptor antagonists)

RN 679790-63-7 USPATFULL

CN Benzeneacetic acid, 4-[[[3-(4-chlorophenyl)propyl](3,5-dimethoxybenzoyl)amino]methyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:17:57 ON 30 MAR 2007)

FILE 'REGISTRY' ENTERED AT 11:18:10 ON 30 MAR 2007

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 1125 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:20:14 ON 30 MAR 2007

L4 4 S L2

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

18.02

191.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

STN INTERNATIONAL LOGOFF AT 11:21:42 ON 30 MAR 2007